Skip to main content
. Author manuscript; available in PMC: 2019 Mar 6.
Published in final edited form as: Kidney Blood Press Res. 2018 Mar 6;43(2):329–349. doi: 10.1159/000487902

Fig. 4.

Fig. 4

Effects of two weeks treatment with renin-angiotensin (RAS) blockade (an angiotensin converting enzyme inhibitor and an angiotensin II receptor blocker) and the two-drug RAS blockade combined with the soluble epoxide hydrolase (sEH) inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid on kidney angiotensin II (ANG II) levels (A), kidney angiotensin-1-7 (ANG 1-7) levels (B), kidney ANG 1-7 to ANG II ratio (C) and in sham-operated Hannover Sprague-Dawley (HanSD, transgene-negative) rats and kidney epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic acids (DHETEs) ratio (D), in heterozygous Ren-2 transgenic rats (TGR), and in 5/6 nephrectomized (5/6 NX) TGR, untreated (water). *P<0.05 compared with sham-operated HanSD rats. #P<0.05 compared with all the other groups.